<?xml version="1.0" encoding="UTF-8"?>
<p id="Par45">VEGF can compromise immune cell function in the tumor microenvironment, which may then become favorable for tumor survival and growth [
 <xref ref-type="bibr" rid="CR11">11</xref>, 
 <xref ref-type="bibr" rid="CR12">12</xref>]. Bevacizumab blocks VEGF receptor signaling [
 <xref ref-type="bibr" rid="CR13">13</xref>]. Anti-VEGF agents can also normalize the tortuous vasculature of tumors and facilitate infiltration of lymphocytes [
 <xref ref-type="bibr" rid="CR11">11</xref>]. Bevacizumab is approved by the Food and Drug Administration for unresectable, locally advanced, recurrent or metastatic non-squamous NSCLC in the first-line setting in combination with carboplatin/paclitaxel [
 <xref ref-type="bibr" rid="CR14">14</xref>â€“
 <xref ref-type="bibr" rid="CR16">16</xref>].
</p>
